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Testing Shortened Versions of Smell Tests
to Screen for Hyposmia in Parkinson’s
Disease
Stephen D. Auger, MRCP, PhD,1 Sofia Kanavou, MSc,2 Michael Lawton, MSc,2 Yoav Ben-Shlomo, MRCP, PhD, FFPH,2
Michele T. Hu, FRCP, PhD,3,4 Anette E. Schrag, FRCP, PhD,5 Huw R. Morris, FRCP, PhD,5 Donald G. Grosset, MD,6 and
Alastair J. Noyce, MRCP, PhD1,7,*
ABSTRACT: Background: Hyposmia is an early feature in neurodegenerative diseases, most notably
Parkinson’s disease (PD). Using abbreviated smell tests could provide a cost-effective means for large-scale
hyposmia screening. It is unclear whether short smell tests can effectively detect hyposmia in patient
populations.
Objectives: To test the ability of short smell combinations to “prescreen” for probable hyposmia in people with
PD and target administration of more extensive tests, such as the University of Pennsylvania Smell
Identification Test.
Methods: We assessed the screening performance of a short 4-smell combination previously derived from use
of the 40-item University of Pennsylvania Smell Identification Test in healthy older people and its ability to
detect hyposmia in a large cohort of PD patients.
Results: The novel 4-smell combination included menthol, clove, onion, and orange and had a sensitivity of
87.1% (95% confidence interval, 84.9%–89.2%) and specificity of 69.7% (63.3%–75.5%) for detecting hyposmia in
patients with PD. A different (also novel) 4-item combination developed using a data-driven approach in PD
patients only achieved 81.3% (78.2%–84.4%) sensitivity for equivalent specificity.
Conclusions: A short 4-smell combination derived from a healthy population demonstrated high sensitivity to
detect those with hyposmia and PD.
Impaired olfaction (hyposmia) is an early feature of neurode-
generative diseases, most notably Parkinson’s disease (PD).1–6
The University of Pennsylvania Smell Identification Test
(UPSIT), comprising 40 “scratch-and-sniff” microencapsulated
odorant strips, is commonly used worldwide.7 We previously
identified short smell combinations derived from the 40-item
UPSIT that could be cost-effective for large-scale hyposmia
screening before targeted administration of the UPSIT.8 That
work was conducted in the healthy general population recruited
to the PREDICT-PD cohort study and was compared with
only a small sample of patients with PD. Here we tested the
screening performance of several short smell combinations in
the Tracking Parkinson’s study that includes data from 1222 peo-
ple with PD.9
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Methods
Validating a Short Smell Test
in People with PD
The performance of 5 smells (menthol, clove, onion, ginger-
bread, and orange) achieved a balance between brevity and high
performance for identifying people with hyposmia against the
full 40-item UPSIT (sensitivity 94.1%) in the PREDICT-PD
pilot cohort’s healthy participants (n = 891 for discovery and
191 for validation, as described previously8).
We assessed screening performance of a combination of 4 of
these 5 smells, omitting gingerbread, in Tracking Parkinson’s 1222
patients. This was because participants in PREDICT-PD used
the 40-item US version of UPSIT, whereas Tracking Parkinson’s
cases completed the 40-item UK version of UPSIT. These
2 UPSIT versions are broadly similar, but 8 of the 40 smells dif-
fer to tailor smells for recognizability in certain populations. We
prioritized cross-cultural smells (those appearing in both the US
and UK UPSIT versions), which did not include gingerbread. A
positive screen for hyposmia using this 4-item combination was
defined when 1 or more smells was identified incorrectly. Posi-
tive and negative screens for hyposmia were compared with
hyposmia defined by performance on the full 40-item test using
the same age-specific and gender-specific thresholds described
previously.8
Deriving a Novel Set of Optimal
Smells in the PD Cohort
We next ran a similar but abridged version of the full analysis we
reported previously.8 We considered all possible combinations of
4, 5, and 6 smells from the full 40 UPSIT smells, testing multiple
different score thresholds for defining hyposmia (ie, at least 1, 2,
3 etc. incorrectly identified smells to denote a positive hyposmia
screen). These results were compared with the participants’ scores
on the full 40-item test in a “discovery” cohort comprising a ran-
domly selected 90% of the participants from Tracking Parkinson’s
(n = 1100). The best-performing combination of smells (defined
by the highest sum of sensitivity and specificity) at each hyposmia
threshold was tested in an independent “validation” cohort com-
prising the remaining 10% of participants (n = 122). We consid-
ered different proportions of data for discovery/validation
(including 50% for each, 75%/25%, 80%/20%, and 95%/5%), but
none achieved notably greater validation screening performance
than 90% for discovery and 10% for validation. Screening perfor-
mance of the best smell combinations is expressed as the values
derived from the independent validation set.
Additional Analyses
We next compared performance of the smell combinations used
in the commercially available 4-item “Pocket Smell Test” to our
novel combinations using the same methods. There are 2 com-
mercially available 4-item “Pocket Smell Tests” (PST-A and
PST-B); these are intended for use as a prescreen for identifying
individuals who require a full UPSIT. The PST-A includes
chocolate, strawberry, smoke, and leather, whereas PST-B
includes grape, which is not included in the UK UPSIT and so
was not further considered.
Finally, we assessed the ability of short smell combinations to
distinguish people with PD (in Tracking Parkinson’s) and those
without (in PREDICT-PD). For this analysis, positive and nega-
tive screens using the same criteria described previously were
compared with whether the individual had a diagnosis of PD
(rather than hyposmia or not).
Results
Validating a Short Smell Test
in People with PD
Based on total UPSIT scores and age-specific and sex-specific
thresholds, 80.9% of participants (988/1222) were classified as
hyposmic in Tracking Parkinson’s. At the time of olfactory testing,
the PD patients had a mean disease duration of 1.89 years (range
0.36–4.50 years). Table 1 shows the screening performance of
the menthol, clove, onion, and orange combination, where 1 or
more incorrectly identified smell was used as a positive screen for
hyposmia. A screen was considered negative if participants identi-
fied all 4 smells correctly. The corresponding screening perfor-
mance values (and 95% confidence intervals) of the 4-item
combination were the following: sensitivity 87.1% (84.9%–
89.2%), specificity 69.7% (63.3%–75.5%), positive predictive
value (PPV) 92.3% (90.9%–93.7%), negative predictive value
(NPV) 56.2% (51.7%–60.7%), positive likelihood ratio (LR+)
2.87 (2.36–3.49), and negative likelihood ratio (LR−) 0.18
(0.15–0.22).
Deriving a Novel Set of Optimal
Smells in the PD Cohort
The optimum combinations of 4, 5, or 6 smells using different cut-
offs to define hyposmia (ie, ≤1, ≤2, ≤3 etc. correctly identified
smells) as identified in a “discovery” cohort of participants is shown
in Figure 1. None of these exceeded the sensitivity of the 4-item
combination used in stage 1 (Fig. 1), but some had higher PPV.
TABLE 1 Screening performance of menthol, clove, onion,
and orange using 1 or more incorrectly identified smell to
define a positive screen, in 1222 people with recent-onset
Parkinson’s disease
True Status
Positive
Screen, n (%)
Negative
Screen, n (%) Total
Hyposmia 861 (87.1) 127 (12.9) 988
Normosmia 71 (30.3) 163 (69.7) 234
Total 932 290 1222
2 MOVEMENT DISORDERS CLINICAL PRACTICE 2020. doi: 10.1002/mdc3.12928
RESEARCH ARTICLE PD HYPOSMIA SCREENING WITH SHORT SMELL TESTS
Additional Analyses
For the commercially available PST-A’s combination of smells, the
screening performance for detecting hyposmia on the UPSIT was
the following: sensitivity 80.2% (77.5%–82.6%), specificity
72.6% (66.5%–78.3%), PPV 92.5% (90.9%–93.9%), NPV 46.4%
(42.8%–50.1%), LR+ 2.93 (2.37–3.62), and LR− 0.27 (0.24–0.32).
Accordingly, the novel 4-smell combination from stage 1 possessed
higher sensitivity for a similar specificity.
For detecting PD cases compared with controls, the screening
performance of the menthol, clove, onion, and orange combi-
nation was the following: sensitivity 76.3% (73.8%–78.6%), speci-
ficity 69.0% (66.2%–71.8%), PPV 73.6% (71.7%–75.4%), NPV
72.0% (69.8%–74.22%), LR+ 2.46 (2.24–2.71), LR− 0.34
(0.31–0.38). As a comparison, the PST-A smells had sensitivity
70.0% (67.4%–72.6%), specificity 60.1% (57.1%–63.0%), PPV
66.5% (64.6%–68.3%), NPV 64.0% (61.7%–66.2%), LR+ 1.75
(1.62–1.90), and LR− 0.50 (0.45–0.55); the full 40-item
UPSIT had sensitivity 80.9% (78.5%–83.0%), specificity 83.7%
(81.4%–85.9%), PPV 84.9% (83.0%–86.6%), NPV 79.5%
(77.5%–81.3%), LR+ 4.97 (4.33–5.71), and LR− 0.23
(0.20–0.26).
Discussion
An abbreviated combination of 4 smells from the UPSIT (men-
thol, clove, onion, and orange) retained high sensitivity for identi-
fying individuals with hyposmia in the context of PD. Previous
work demonstrated that these 4 smells, as well as gingerbread,
have high screening performance for detecting hyposmia in a gen-
eral population and hinted toward similar screening performance
in people with PD,8 an observation that is borne out in the cur-
rent analyses. This combination of 4 smells also outperformed
smells in the commercially available PST-A in differentiating PD
cases from controls (on account of high prevalence of hyposmia in
PD). Although it performed less well when compared with the
40-item UPSIT, these data suggest that abbreviated tests used as a
screen in the prediagnostic phase of PD will not systematically miss
a large proportion of those with PD-related olfactory dysfunction.
Our proposed application for an abbreviated smell test would
be as part of a 2-step approach, whereby individuals complete an
abbreviated test as a quick and cost-effective prescreen to identify
individuals who might be pertinent to consider for full-smell
testing. Maintaining high sensitivity would be most important
for an abbreviated smell test used in this way to ensure that most
FIG. 1. Screening performance in the validation cohort for each “winning” smell combination at the different cut-offs used for defining
hyposmia for subsets of 4 to 6 smells. The 4-smell combination described in stage 1 is included at the top for comparison. Cell shading
corresponds to the value of the number they contain. Values below 50 contain no shading, darker shading corresponds to higher values
(in brackets of 5). The highest value in each category is underlined. PPV, positive predictive value; NPV, negative predictive value.
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people who require full testing are identified while allowing
more cost-effective, targeted administration of the full UPSIT.
For example, sending a full UPSIT ($26.95 per test) to identify
hyposmia in a cohort of 10,000 healthy older people would cost
$269,500. Postage costs, based on UK pricing, would amount to
$4 return for each participant ($40,000 total). Using this 4-item
prescreen ($3.95 per test), 31.0% in the PREDICT-PD study
screen positive and would also be sent a full UPSIT (total cost in
tests $122,940). The 2-step approach generates different postage
costs as well. The lighter weight of a 4-item test costs $2 return
in the UK ($20,000 for 10,000 participants), with 31.0% incur-
ring a second return postage cost of $4 for the full UPSIT
($12,400 for 10,000 participants). Hence, the total cost for
nondiscriminative UPSIT administration versus using this 4-item
prescreen amounts to $309,500 versus $155,340, respectively.
Given the 4-item combination’s 87.1% sensitivity for detecting
hyposmia here, this halving of cost would come at the expense
of missing approximately 10% to 15% of people in whom full
UPSIT testing would have identified hyposmia.
The attempt to derive a novel “PD-specific” abbreviated smell
combination (stage 2) was notable for the much greater variability
in smells featuring in winning combinations than was present using
the PREDICT-PD cohort’s general population. This perhaps
reflects greater variability and more erratic trends in olfactory dys-
function in PD cases than controls. Indeed, this is borne out in the
fact that the 4 smells identified as performing best in PREDICT-
PD’s general population outperformed the corresponding “winning”
subset of 4 smells with hyposmia cutoff ≤3 derived from people with
PD in every regard (sensitivity 87.1% vs. 81.3%, specificity 69.7%
vs. 61.5%, PPV 92.3% vs. 88.6%, and NPV 56.2% vs. 40.7%,
respectively). This adds further weight to the finding that the high-
performing smells identified in PREDICT-PD’s general population
are a reliable marker for screening hyposmia.
Some limitations need to be noted. The high hyposmia preva-
lence (using UPSIT) in this cohort of people with PD (80.9%) is
expected given the strong association between hyposmia and
PD. In the PREDICT-PD general population, hyposmia preva-
lence using the same criteria was 16.2%. This warrants attention as
high prevalence drives higher PPV and lower NPV. Indeed, as is
clear in Figure 1, PPV was consistently higher than NPV for every
smell combination in the Tracking Parkinson’s participants. Great
care is necessary if attempting to extrapolate PPV/NPV to other
populations given their high context dependency. There are likely
to be other sociodemographic differences between PREDICT-PD
and Tracking Parkinson’s participants in addition to disease status.
These potential confounders could have influenced test perfor-
mance, but the observation that the original 4 smells outperformed
the data-driven approach suggests this was limited. The analysis also
extrapolated the performance of 4-item smell tests from 4-smell
combinations taken within a larger 40-item smell test. There is a
chance that true performance with dedicated 4-item tests may differ
from the 4-smell combinations identified in this work.
Our 4-smell combination retains a degree of cross-cultural rel-
evance given that all 4 smells feature in both the UK and US ver-
sions of the UPSIT. However, testing here was only in
individuals based in the United Kingdom, including a fairly
restricted set of ethnicities. Further validation would be required
including other ethnic minorities and in other countries to assess
broader external validity. There also remain some unavoidable
differences between the UK and US versions, most notably the
use of different distractor options for some smells. In the analysis
of screening performance for identifying PD cases versus controls,
the cases (in Tracking Parkinson’s) all completed the UK version of
the UPSIT, whereas the controls (in PREDICT-PD) completed
the US version. This could have impaired performance of controls
versus cases given that it was a UK population completing a US
test version. However, this would likely have led to
the underestimation rather than the overestimation of screening
performance owing to a reduced difference between cases and
controls.
Prospective follow-up of these and similar cohorts will be able
to provide additional information regarding possible clinical
implications of having hyposmia in people already diagnosed
with PD or whether disease duration is related to the incidence
of hyposmia.
In conclusion, the abbreviated 4-smell combination of menthol,
clove, onion, and orange retains high sensitivity to detect those
with hyposmia in the context of PD. This subset of smells has
cross-cultural relevance and outperformed attempts to derive a sep-
arate PD-specific combination of smells for hyposmia screening.
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